Cargando…
Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
Background: pemafibrate is a newly-introduced selective peroxisome proliferator-activated receptor-α modulator, which decreases serum triglyceride levels with few drug-related adverse events and may reduce the risk of adverse cardiovascular events in carefully selected patients with hypertriglycerid...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821179/ https://www.ncbi.nlm.nih.gov/pubmed/36614823 http://dx.doi.org/10.3390/jcm12010021 |